YU1402A - Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama - Google Patents

Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama

Info

Publication number
YU1402A
YU1402A YU1402A YUP1402A YU1402A YU 1402 A YU1402 A YU 1402A YU 1402 A YU1402 A YU 1402A YU P1402 A YUP1402 A YU P1402A YU 1402 A YU1402 A YU 1402A
Authority
YU
Yugoslavia
Prior art keywords
pharmacokinetic properties
core polypeptide
hybrid polypeptides
peptide sequences
core
Prior art date
Application number
YU1402A
Other languages
English (en)
Inventor
Shawn Barney
Kelly I. Guthrie
Gene Merutka
Mohamed K. Anwer
Dennis M. Lambert
Original Assignee
Trimeris Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc. filed Critical Trimeris Inc.
Publication of YU1402A publication Critical patent/YU1402A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak se odnosi na pojacavajuce peptidne sekvence koje originalno poticu iz razlicitih retrovirusnih obuhvatnih (omotanih) (gp41) proteinskih sekvenci koje pojacavaju farmakokineticke osobine bilo kojeg centralnog (osnovnog) polipeptida za koji su vezane. Ovaj pronalazak se bazira na otkricu da hibridni polipeptidi koji obuhvataju pojacavajuce peptidne sekvence vezane za centralni (osnovni) polipeptid imaju pojacane farmakokineticke osobine kao sto je povecan poluzivot. Ovaj pronalazak se dalje odnosi na postupke za pojacavanje farmakokinetickih osobina bilo kojeg centralnog (osnovnog) polipeptida preko vezivanja pojacavajucih peptidnih sekvenci za centralni (osnovni) polipeptid. Centralni (osnovni) polipeptidi koji se trebaju koristiti u praksi ovog pronalaska mogu ukljucivati bilo koji farmakoloski prihvatljiv (podesan) peptid koji se moze primeniti, na primer, kao terapeutski ili profilakticki reagens.
YU1402A 1999-07-09 2000-07-10 Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama YU1402A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/350,641 US6656906B1 (en) 1998-05-20 1999-07-09 Hybrid polypeptides with enhanced pharmacokinetic properties

Publications (1)

Publication Number Publication Date
YU1402A true YU1402A (sh) 2004-11-25

Family

ID=23377584

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1402A YU1402A (sh) 1999-07-09 2000-07-10 Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama

Country Status (22)

Country Link
US (2) US6656906B1 (sh)
EP (1) EP1206272A4 (sh)
JP (1) JP2003504344A (sh)
KR (1) KR100755418B1 (sh)
CN (1) CN1254271C (sh)
AR (1) AR024699A1 (sh)
AU (1) AU6082200A (sh)
BR (1) BR0012287A (sh)
CA (1) CA2377677A1 (sh)
CZ (1) CZ200288A3 (sh)
HK (1) HK1045259A1 (sh)
HR (1) HRP20020022A2 (sh)
IL (1) IL147331A0 (sh)
MX (1) MXPA02000012A (sh)
NO (1) NO20020087L (sh)
NZ (1) NZ516550A (sh)
PL (1) PL352685A1 (sh)
RU (1) RU2279883C2 (sh)
TR (1) TR200200766T2 (sh)
TW (1) TWI248364B (sh)
WO (1) WO2001003723A1 (sh)
YU (1) YU1402A (sh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
ES2296665T3 (es) 1999-12-16 2008-05-01 Whitehead Institute For Biomedical Research Proteina cinco-helice.
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CN1255548C (zh) 2001-06-15 2006-05-10 霍夫曼-拉罗奇有限公司 gp41片段的乙酰化
WO2003074691A1 (fr) * 2002-03-01 2003-09-12 National Institute Of Advanced Industrial Science And Technology Cellules et liposomes immobilises et procede d'immobilisation correspondant
EP1545371B1 (en) * 2002-08-01 2016-04-13 Robert A. Levine Cardiac devices and methods for minimally invasive repair of ischemic mitral regurgitation
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2521393A1 (en) * 2003-04-04 2004-10-14 Universite De Lausanne Peptabody for cancer treatment
WO2004106364A1 (en) * 2003-08-05 2004-12-09 Cornell Research Foundation, Inc. Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors
JP2007515965A (ja) 2003-12-23 2007-06-21 セントカー・インコーポレーテツド 抗レトロウイルス性の剤、組成物、方法および用途
WO2005067960A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
EP1725262B1 (en) * 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
WO2005118886A2 (en) * 2004-06-01 2005-12-15 Merck & Co., Inc. Stable peptide mimetic of hiv gp41 fusion intermediate
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP1868652A2 (en) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
CA2651793C (en) * 2006-02-02 2015-07-07 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ccr5 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2125876A1 (en) * 2007-03-12 2009-12-02 Thomas Jefferson University Tighter-binding c-peptide inhibitors of hiv-1 entry
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
EP2139526A4 (en) * 2007-04-03 2010-07-14 Trimeris Inc NEW FORMULATIONS TO RELEASE ANTIVIRAL PEPTIDE THERAPEUTICS
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
EP2170314B1 (en) * 2007-05-24 2013-10-02 The Board of Regents of The University of Texas System Methods and compositions for treating phenylketonuria
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス,インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2011060352A1 (en) 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
CN103108884A (zh) 2010-09-14 2013-05-15 弗·哈夫曼-拉罗切有限公司 Serpin-finger融合多肽
CN104136455B (zh) * 2012-02-27 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 抗hiv‑1多肽及其用途
CN104039815A (zh) * 2012-02-28 2014-09-10 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018081832A1 (en) * 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US20210154327A1 (en) * 2017-08-29 2021-05-27 Pharis Biotec Gmbh Protransduzin-d - improved enhancer of gene transfer
US20220283151A1 (en) * 2021-03-05 2022-09-08 Brigham Young University Method for controlling protein dimerization using an intramolecular to intermolecular conformational switch
CN116162136B (zh) * 2021-11-24 2024-08-23 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0272858A3 (en) 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
AU626797B2 (en) 1987-09-08 1992-08-13 Albany Medical College Immunogenic composites capable of selectively inducing antibody production, pharmaceutical compositions employing the same and method of selectively inducing antibody production
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis

Also Published As

Publication number Publication date
WO2001003723A9 (en) 2002-07-25
TWI248364B (en) 2006-02-01
MXPA02000012A (es) 2003-07-21
WO2001003723A1 (en) 2001-01-18
EP1206272A1 (en) 2002-05-22
CA2377677A1 (en) 2001-01-18
HRP20020022A2 (en) 2004-02-29
CN1254271C (zh) 2006-05-03
PL352685A1 (en) 2003-09-08
EP1206272A4 (en) 2003-01-02
AU6082200A (en) 2001-01-30
US7297784B2 (en) 2007-11-20
CZ200288A3 (cs) 2002-06-12
JP2003504344A (ja) 2003-02-04
AR024699A1 (es) 2002-10-23
CN1373669A (zh) 2002-10-09
KR100755418B1 (ko) 2007-09-05
HK1045259A1 (zh) 2002-11-22
BR0012287A (pt) 2002-04-02
RU2279883C2 (ru) 2006-07-20
NO20020087L (no) 2002-03-01
TR200200766T2 (tr) 2002-10-21
US6656906B1 (en) 2003-12-02
NO20020087D0 (no) 2002-01-08
KR20020029667A (ko) 2002-04-19
NZ516550A (en) 2004-05-28
IL147331A0 (en) 2002-08-14
US20030186874A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
YU1402A (sh) Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama
TR200100163T2 (tr) Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler
Hackeng et al. Total chemical synthesis of human matrix Gla protein
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
SI1346034T1 (sl) POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA
IL212140A0 (en) Antibodies against acpl polypeptides
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
EP2360259A3 (en) Promyostatin peptides and methods of using same
ATE349700T1 (de) Übergangsmetallkomplex-haltige lumineszente proteinfarben
GB9712512D0 (en) A method for in vitro molecular evolution of protein function
PT989999E (pt) Composicao anti-tumoral a base de polipeptido imunogenico de localizacao celular modificada
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
DE69132902D1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
ATE370160T1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
AU5776799A (en) Modified hcv peptide vaccines
AU2003239659A1 (en) Peptide epitopes common to antigens of the same multigene family
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
AU2865801A (en) Therapeutic peptides
AU5163500A (en) Il-1 eta dna and polypeptides
DE69932247D1 (de) Menschlisches il-1 epsilon dna und polypeptide
NZ503852A (en) Death associated kinase containing ankyrin repeats (DAKAR)